Lisbeth Marner1,2,3, Michael Lundemann1, Astrid Sehested4, Karsten Nysom4, Lise Borgwardt1, René Mathiasen4, Peder S Wehner5, Otto M Henriksen1, Carsten Thomsen6,7, Jane Skjøth-Rasmussen8, Helle Broholm9, Olga Østrup10, Julie L Forman11, Liselotte Højgaard1, Ian Law1. 1. Department of Clinical Physiology, Nuclear Medicine and PET, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 2. Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 3. Department of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Bispebjerg, Copenhagen, Denmark. 4. Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 5. Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark. 6. Department of Diagnostic Radiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 7. Department of Radiology, Zealand University Hospital, Roskilde, Denmark. 8. Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 9. Department of Pathology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 10. Department of Genomic Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. 11. Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark.
Abstract
BACKGROUND: Central nervous system (CNS) tumors cause the highest death rates among childhood cancers, and survivors frequently have severe late effects. Magnetic resonance imaging (MRI) is the imaging modality of choice, but its specificity can be challenged by treatment-induced signal changes. In adults, O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) PET can assist in interpreting MRI findings. We assessed the clinical impact and diagnostic accuracy of adding [18F]FET PET to MRI in children with CNS tumors. METHODS: A total of 169 [18F]FET PET scans were performed in 97 prospectively and consecutively included patients with known or suspected childhood CNS tumors. Scans were performed at primary diagnosis, before or after treatment, or at relapse. RESULTS: Adding [18F]FET PET to MRI impacted clinical management in 8% [95% confidence interval (CI): 4%-13%] of all scans (n = 151) and in 33% [CI: 17%-53%] of scans deemed clinically indicated due to difficult decision making on MRI alone (n = 30). Using pathology or follow-up as reference standard, the addition of [18F]FET PET increased specificity (1.00 [0.82-1.00] vs 0.48 [0.30-0.70], P = .0001) and accuracy (0.91 [CI: 0.87-0.96] vs 0.81 [CI: 0.75-0.89], P = .04) in 83 treated lesions and accuracy in 58 untreated lesions (0.96 [CI: 0.91-1.00] vs 0.90 [CI: 0.82-0.92], P < .001). Further, in a subset of patients (n = 15) [18F]FET uptake correlated positively with genomic proliferation index. CONCLUSIONS: The addition of [18F]FET PET to MRI helped discriminate tumor from non-tumor lesions in the largest consecutive cohort of pediatric CNS tumor patients presented to date.
BACKGROUND: Central nervous system (CNS) tumors cause the highest death rates among childhood cancers, and survivors frequently have severe late effects. Magnetic resonance imaging (MRI) is the imaging modality of choice, but its specificity can be challenged by treatment-induced signal changes. In adults, O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET) PET can assist in interpreting MRI findings. We assessed the clinical impact and diagnostic accuracy of adding [18F]FET PET to MRI in children with CNS tumors. METHODS: A total of 169 [18F]FET PET scans were performed in 97 prospectively and consecutively included patients with known or suspected childhood CNS tumors. Scans were performed at primary diagnosis, before or after treatment, or at relapse. RESULTS: Adding [18F]FET PET to MRI impacted clinical management in 8% [95% confidence interval (CI): 4%-13%] of all scans (n = 151) and in 33% [CI: 17%-53%] of scans deemed clinically indicated due to difficult decision making on MRI alone (n = 30). Using pathology or follow-up as reference standard, the addition of [18F]FET PET increased specificity (1.00 [0.82-1.00] vs 0.48 [0.30-0.70], P = .0001) and accuracy (0.91 [CI: 0.87-0.96] vs 0.81 [CI: 0.75-0.89], P = .04) in 83 treated lesions and accuracy in 58 untreated lesions (0.96 [CI: 0.91-1.00] vs 0.90 [CI: 0.82-0.92], P < .001). Further, in a subset of patients (n = 15) [18F]FET uptake correlated positively with genomic proliferation index. CONCLUSIONS: The addition of [18F]FET PET to MRI helped discriminate tumor from non-tumor lesions in the largest consecutive cohort of pediatric CNS tumor patients presented to date.
Authors: Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn Journal: Neuro Oncol Date: 2016-04-21 Impact factor: 12.300
Authors: Benoit Pirotte; Marc Levivier; Daniele Morelli; Patrick Van Bogaert; Dominique Detemmerman; Philippe David; Daniele Baleriaux; Jacques Brotchi; Serge Goldman Journal: Childs Nerv Syst Date: 2004-12-10 Impact factor: 1.475
Authors: Jason Fangusaro; Olaf Witt; Pablo Hernáiz Driever; Asim K Bag; Peter de Blank; Nadja Kadom; Lindsay Kilburn; Robert M Lober; Nathan J Robison; Michael J Fisher; Roger J Packer; Tina Young Poussaint; Ludmila Papusha; Shivaram Avula; Alba A Brandes; Eric Bouffet; Daniel Bowers; Anton Artemov; Murali Chintagumpala; David Zurakowski; Martin van den Bent; Brigitte Bison; Kristen W Yeom; Walter Taal; Katherine E Warren Journal: Lancet Oncol Date: 2020-06 Impact factor: 41.316
Authors: Marion Rapp; Alexander Heinzel; Norbert Galldiks; Gabriele Stoffels; Jörg Felsberg; Christian Ewelt; Michael Sabel; Hans J Steiger; Guido Reifenberger; Thomas Beez; Heinz H Coenen; Frank W Floeth; Karl-Josef Langen Journal: J Nucl Med Date: 2012-12-11 Impact factor: 10.057
Authors: Christopher L Tinkle; Elizabeth C Duncan; Mikhail Doubrovin; Yuanyuan Han; Yimei Li; Hyun Kim; Alberto Broniscer; Scott E Snyder; Thomas E Merchant; Barry L Shulkin Journal: J Nucl Med Date: 2018-08-02 Impact factor: 10.057
Authors: Otto M Henriksen; Vibeke A Larsen; Aida Muhic; Adam E Hansen; Henrik B W Larsson; Hans S Poulsen; Ian Law Journal: Eur J Nucl Med Mol Imaging Date: 2015-09-12 Impact factor: 9.236
Authors: Jonas Vikeså; Anne Kirstine H Møller; Bogumil Kaczkowski; Rehannah Borup; Ole Winther; Ricardo Henao; Anders Krogh; Katharina Perell; Flemming Jensen; Gedske Daugaard; Finn C Nielsen Journal: BMC Cancer Date: 2015-03-19 Impact factor: 4.430
Authors: Norbert Galldiks; Lutz W Kracht; Frank Berthold; Hrvoje Miletic; Johannes C Klein; Karl Herholz; Andreas H Jacobs; Wolf-Dieter Heiss Journal: J Neurooncol Date: 2009-07-04 Impact factor: 4.130
Authors: Otto M Henriksen; Adam E Hansen; Aida Muhic; Lisbeth Marner; Karine Madsen; Søren Møller; Benedikte Hasselbalch; Michael J Lundemann; David Scheie; Jane Skjøth-Rasmussen; Hans S Poulsen; Vibeke A Larsen; Henrik B W Larsson; Ian Law Journal: Eur J Nucl Med Mol Imaging Date: 2022-07-30 Impact factor: 10.057
Authors: Asim K Bag; Melissa N Wing; Noah D Sabin; Scott N Hwang; Gregory T Armstrong; Yuanyuan Han; Yimei Li; Scott E Snyder; Giles W Robinson; Ibrahim Qaddoumi; Alberto Broniscer; John T Lucas; Barry L Shulkin Journal: J Nucl Med Date: 2021-08-26 Impact factor: 10.057
Authors: Arnoldo Piccardo; Nathalie L Albert; Lise Borgwardt; Frederic H Fahey; Darren Hargrave; Norbert Galldiks; Nina Jehanno; Lars Kurch; Ian Law; Ruth Lim; Egesta Lopci; Lisbeth Marner; Giovanni Morana; Tina Young Poussaint; Victor J Seghers; Barry L Shulkin; Katherine E Warren; Tatjana Traub-Weidinger; Pietro Zucchetta Journal: Eur J Nucl Med Mol Imaging Date: 2022-05-10 Impact factor: 10.057